“The problem facing our biomedical industry has been that most vaccine and drug candidates needed to be sent overseas to be produced in large quantities for clinical trials, adding burdensome costs that have crushed many Australian businesses and researchers as the invention languishes on the lab bench," saod CSIRO chief executive Dr Larry Marshall.
CSIRO opens 'missing link' lab to develop Australian vaccine pipeline
August 12, 2022 Latest NewsBioPharma
Latest Video
New Stories
-
Australian researchers solve decades-long mystery on Parkinson’s disease
March 14, 2025 - - Australian Biotech -
Kosi climbers about to embark on day one of 2025 challenge
March 14, 2025 - - Latest News -
Astellas cancer therapy approved for new indication in earlier prostate cancer
March 14, 2025 - - Latest News -
World-first study identifies 'Goldilocks' number of genes to include in pre-pregnancy screening
March 13, 2025 - - Latest News -
Medicines funded by Pharmac tops 50 since last year's budget boost
March 13, 2025 - - Latest News -
Australia is not alone in using rebate payments, but there are some differences
March 13, 2025 - - Latest News -
Australian company confirms the location of key clinical trial
March 13, 2025 - - Australian Biotech